The regiospecific addition of bromine azide to the vinyl substituent of 5-vinyl-3',5'-di-0-acetyl-(or tertbutyldimethylsily1)-2'-deoxyuridines (2) yielded the corresponding 5-(1-azido-2-bromoethyl)-3',5'-di-O-protected-2'-deoxyuridines (3). Treatment of the 5-(1 -azido-2-bromoethyl) compounds 3 with t-BuOK, to effect the base-catalyzed elimination of HBr, afforded the corresponding 5-(I-azidoviny1)-2'-deoxyuridines (4,7). Thermal decomposition of 5-(1-azidoviny1)-2'-deoxyuridine (7) at 1 10°C in dioxane yielded 5-[2-( 1 -azirinyl)]-2'-deoxyuridine (9). 5-( 1 -Azidoviny 1)-2'-deoxyuridine (7) exhibited appreciable in vitro antiviral activities againist herpes simplex virus type 1 (HSV-1) and varizella zoster virus (VZV). Athough 7 increased the length of survival of HSV-1 brain-infected mice, it did not decrease the mortality rate relative to placebo. 5-[2-(1-Azirinyl)]-2'-deoxyuridine (9) was an inactive antiviral agent.Key words: azidovinyl, azirinyl, 2'-deoxyuridine, antiviral activity.RCsumC : L'addition rCgiospCcifique de l'azoture de brome sur le substituant vinylique des 5-vinyl-3'-di-0-acCtyl-(ou tertbutyldimCthylsilyl)-2'-dCsoxyuridines (2) conduit aux 5-(1-azido-2-bromoCthyl)-3',5'-protCgC-2'-dCs0xyuridines (3). Le traitement des composCs 3 par le t-BuOK provoque une Climination basocatalysCe de HBr qui conduit aux 5-(1-azidoviny1)-2'-dCsoxyuridines (4,7). La dCcomposition thermique de la 5-(azidoviny1)-2'-dCsoxyuridine (7), j. 1 10°C, dans le dioxane, foumit de la 5-12-(1-azirinyl)]-2'-dCsoxyuridine (9). La 5-(1-azidoviny1)-2'-dCsoxyuridine (7) prCsente des activitCs antiviral in vitro apprCciables contre le virus de l'herpks simplex de type I (HSV-1) et le virus zoster varizella (VZV). M&me si le composC 7 augmente le temps de survie des souris dont le cerveau a CtC infect6 au HSV-I, il ne diminue pas le taux de mortalit6 par rapport au placebo. Le 5-[2-(1-azirinyl)]-2'-dCsoxyuridine (9) n'est pas actif comme agent antiviral. The development of new methods for the synthesis of 2'-deoxyuridines that possess novel vinyl moieties at the C-5 position and exhibit potent antiviral activity represents an important area of drug design. 5-Vinyl-2'-deoxyuridine ( l a ) has been shown to exhibit potent antiviral activity against herpes simplex virus type-1 (HSV-l), type-2 (HSV-2), and vaccinia virus (1). Among the many 5-substituted pyrimidine nucleosides that have been studied, (E)-5-(2-halovinyl)-2'-deoxyuridines (lb; X = I (IVDU); X = Br (BVDU); X = C1 (CVDU)) are among the most active and selective in their action against HSV-1 (2). Incorporation of a methyl substituent at the l-position of the 5-(2-bromovinyl) moiety of BVDU (lc) (3), or a chloro substituent at the 1-position of the 5-vinyl moiety of VDU (16) (4), reduced activity against HSV-1. Structureactivity correlations for a group of 5-substituted-2'-deoxyuridines indicated that optimum antiviral activity against HSV-1 occurs when the C-5 substituent is unsaturated and conjugated with the uracil ring, is not larger than four atoms in length...